Adaptive Family Treatment for Adolescent Anorexia Nervosa
|ClinicalTrials.gov Identifier: NCT01579682|
Recruitment Status : Completed
First Posted : April 18, 2012
Last Update Posted : April 13, 2016
|Condition or disease||Intervention/treatment||Phase|
|Anorexia Nervosa||Behavioral: Family-Based Therapy (FBT) Behavioral: Family-Based Therapy with Intensive Family-Focused treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adaptive Family Treatment for Adolescent Anorexia Nervosa|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Family-Based Therapy (12 sessions)
Behavioral: Family-Based Therapy (FBT)
12 sessions of FBT over the course of 6 months.
Experimental: Family-Based Therapy with Intensive Family-Focused Treatment
The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
Behavioral: Family-Based Therapy with Intensive Family-Focused treatment
FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
- Full remission from AN (%MBW>95) [ Time Frame: End of Treatment (6 months) ]Weight restoration to at least 95% of Median body weight (calculated by height, weight, gender, and age)
- Changes in subscale scores of the EDE [ Time Frame: End of Treatment (6 months) ]Eating Disorder Examination subscale measures (weight concern, shape concern, dietary restraint) within 1 standard deviation of normative scores.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01579682
|United States, California|
|Stanford, California, United States, 94305|
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||James D Lock, MD, PhD||Stanford University|
|Principal Investigator:||Daniel LeGrange, PhD||University of Chicago|